UNSPSC 51112805: Toremifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C26H28ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NFE54O27T, chemically known as 2-(p-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethylamine citrate (1:1) but more generally known as toremifene, which bears US NIH Compound Identifier 3005572. European Medicines Agency schedules Toremifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11197MIG.

UNSPSC 51112805 Toremifene is a Commodity code naming a specific pharmaceutical product — an estrogen receptor antagonist used in breast cancer treatment. State and local governments procure toremifene primarily through pharmacy benefit managers, group purchasing organizations, and direct pharmaceutical supply channels as part of their Medicaid programs, employee health plans, and state health agency formularies. The work under this code involves the procurement, distribution, and cost management of toremifene tablets and related formulations to support eligible beneficiaries and covered lives across state and local health systems.

The Texas Health and Human Services Commission recently issued a Request for Information (RFI No. HHS0017013, posted April 3, 2026, with a response deadline the same day) to explore direct-to-manufacturer prescription programs and vendor capabilities for fulfilling pharmaceutical product requirements outside traditional pharmacy benefit manager and group purchasing organization channels. This exploratory RFI signals Texas HHS interest in alternative procurement models for pharmacy products including toremifene, seeking vendor experience with direct contracting, negotiated net pricing, and value-based or outcomes-based agreements. The RFI represents foundational market intelligence gathering before formal competitive solicitation; no award values, budget ranges, or set-aside designations are identified at this stage. Geographic activity under this Commodity code remains concentrated in Texas based on available recent opportunities; broader state and local pharmaceutical procurement activity under this code is not documented in current solicitation records.